Shanghai, China – September 15, 2026 – Frost & Sullivan announced the release of its new White Book titled “Current Landscape and Future Trends of the Gut Microbiota Industry.” The report offers an in‑depth look at the science, market dynamics, and regulatory environment shaping gut microbiota‑based therapeutics and health products worldwide.
Key Findings
The White Book notes that gut microbiota, often called the “second genome,” plays a crucial role in energy balance, immune regulation, and disease progression. Advances in omics, gene editing, and synthetic biology have propelled live biotherapeutic products (LBPs) into the forefront of drug development. Unlike conventional probiotics, LBPs must meet rigorous pharmaceutical standards for safety, efficacy, and manufacturing.
Clinical development is concentrated in China, the United States, Europe, and Canada. Fecal microbiota transplantation (FMT) accounts for roughly 44.2% of active pipelines, while single‑strain microbial therapeutics represent about 30% of projects. Several candidates have entered late‑stage trials, promising new treatment options for hard‑to‑treat conditions such as inflammatory bowel disease and Clostridioides difficile infection.
Market Drivers and Growth
Chinese companies are expanding globally, buoyed by strong domestic demand, rising investment, and supportive government policies. China leads in microbiota‑related patent filings, contributing 33% of global applications. International initiatives from the United States, the European Union, and other regions further stimulate research and commercial activity.
The report highlights a shift toward personalized health solutions, integrating diagnostics, digital tools, and therapeutic products. A clearer regulatory framework is expected to standardize safety standards for genetically modified microbial strains and FMT, fostering sustained industry growth.
Industry Structure
The gut microbiota value chain comprises three segments: upstream providers of sequencing platforms and microbial strains; midstream developers of therapeutics and functional health products; and downstream users, including clinical institutions and consumers. The midstream segment is identified as the primary value‑creation stage.
Frost & Sullivan’s White Book also outlines financing trends, noting increased capital flow into both Chinese and global microbiota companies, and compares policy environments across major markets.
About Frost & Sullivan
Frost & Sullivan, a growth‑partnership firm with over 65 years of experience, delivers market research, benchmarking, and strategic consulting across multiple sectors, including healthcare, advanced technology, and new energy.
Original reporting: KTBS 3 (Shreveport) — read the source article.
